Exiqon A/S completes litigation against Santaris Pharma a/s
October 7, 2011
Exiqon A/S today announced that the company has completed its litigation against Santaris Pharma a/s. In 2010, Exiqon initiated arbitration proceedings to defend its business against Santaris Pharma. Exiqon’s product offering includes LNA™ amidites and LNA™ oligonucleotides for the research and development of pharmaceutical products. Exiqon has the exclusive right to supply such products except [...]
Establishment of Analytical & Measuring Instrument Sales Company in RSA
October 7, 2011
As part of its efforts to promote globalization and to enhance the sales and service structure in southern African markets, Shimadzu Corporation's wholly owned subsidiary in the United Arab Emirates, Shimadzu Middle East & Africa FZE (SMEA), established a wholly owned sales subsidiary, Shimadzu South Africa (Pty) Limited (SSA), on October 1 in the Republic [...]
October 7, 2011
CHIBA, Japan--Transparent Inc. and Molecular Response LLC, with the world's largest primary tumor bank that contains more than 144,000 primary tumor specimens, accelerate collaborative research efforts to develop the next generation of 3 dimensional cell-culture systems for cancer research. Improved preclinical models are required to advance our understanding of the molecular aberrations that underpin cancer [...]
ProteinSimple to Offer Direct Sales, Service and Support for Biologics Products in Europe
October 7, 2011
SANTA CLARA, Calif. -- ProteinSimple today announced plans to provide direct sales, field applications and field service support for its biologics products in Europe, effective January 1, 2012. Two industry-leading product lines are included in this expanded support structure: iCE Imaged Capillary Electrophoresis systems and MFI Micro-Flow Imaging systems. The biologics market segment is a [...]
October 7, 2011
La Jolla, CA - Prognosys Biosciences® is pleased to announce Voila!™, a new cloud-based data analysis service for next-generation sequencing data. Voila! will be available initially for RNA sequencing projects that utilize data from Illumina® HiSeq and GAIIx next-generation sequencing instruments. Researchers working with RNA sequencing data face many analysis challenges, ranging from the size [...]
Thorlabs Expands Life Science Offerings with Burleigh® Acquisition
October 7, 2011
Newton, NJ, USA and Mississauga, Ontario, CANADA – Thorlabs, Inc. of Newton, NJ and Lumen Dynamics Group, Inc. of Mississauga, Ontario jointly announced today Thorlabs’ acquisition of the Burleigh® product line assets of Lumen Dynamics. Burleigh is a world leader in manufacturing a wide range of manipulation and precision motion control equipment for applications within [...]
Tecan Initiates CEO Succession Process
October 7, 2011
Männedorf, Switzerland – The Tecan Group (SIX Swiss Exchange: TECN) today announced that the Board of Directors has initiated a succession process for the top management position. In the coming months, the Board of Directors will elect a new CEO who will continue implementing Tecan’s growth strategy. Thomas Bachmann, CEO of the Group since the [...]
Lumen Dynamics Sells Burleigh Product Line
October 7, 2011
Mississauga, Ontario, CANADA - Lumen Dynamics Group Inc. announced today that it has sold its Burleigh® product line to Thorlabs Inc, a leader in photonics equipment for the scientific market. Burleigh® products include piezoelectric micromanipulators and microscope mounting systems for the life science research market. The divestiture will allow the Burleigh® product line to be [...]
Illumina Announces Preliminary Revenue for Third Quarter 2011
October 6, 2011
Illumina, Inc. today announced estimated third quarter revenue of approximately $235 million. This estimate is based on management's preliminary financial review and remains subject to review by our independent registered public accounting firm. We currently believe the following factors negatively affected our revenue in the third quarter compared to our forecast: Continued uncertainty surrounding the [...]
Exiqon A/S – Exiqon and Roswell Park sign Center of Excellence Agreement
October 6, 2011
Exiqon A/S, a leading supplier of high-value gene expression analysis products, and Health Research, Inc., Roswell Park Cancer Institute Division, where groundbreaking research by Roswell Park scientists has led to greater understanding of the nature of cancer and to major advances in cancer diagnostics and treatments that are now in use worldwide, today announced that [...]
